Contributors |
|
xix | |
Interactive Topical Discussion on AIDS Neurology: Past, Present, and Future |
|
xxix | |
|
|
|
|
|
|
|
|
|
|
|
|
|
Section 1 HIV-1 Biology And Immunology |
|
|
|
|
3 | (19) |
|
|
|
|
22 | (14) |
|
|
|
|
|
|
36 | (14) |
|
|
1.4 Viral and Host Genetic Factors |
|
|
50 | (21) |
|
|
|
|
|
1.5 Genetic Susceptibilities for NeuroAIDS |
|
|
71 | (22) |
|
|
|
|
|
|
Section 2 Innate And Cellular Immunity And Neurogenesis |
|
|
|
2.1 Mononuclear Phagocytes |
|
|
93 | (16) |
|
|
|
|
|
|
109 | (10) |
|
|
|
119 | (12) |
|
|
|
|
|
131 | (15) |
|
Jessica A. L. Hutter-Saunders |
|
|
|
|
|
|
146 | (27) |
|
|
|
|
|
173 | (16) |
|
|
|
|
|
|
Section 3 Blood-Brain Barrier And HIV CNS Entry |
|
|
|
3.1 Blood-Brain Barrier: Structure and Function |
|
|
189 | (18) |
|
|
3.2 Endothelial Cell Biology and HIV-1 Infection |
|
|
207 | (13) |
|
|
|
|
|
|
3.3 Blood-Brain Barrier during Neuroinflammation |
|
|
220 | (11) |
|
|
|
3.4 Mechanisms of Viral and Cell Entry into the Central Nervous System |
|
|
231 | (15) |
|
|
|
3.5 Monocyte-Macrophages and Viral Central Nervous System Entry |
|
|
246 | (11) |
|
|
Section 4 Cellular and Viral Neurotoxicity and Abused Drugs |
|
|
|
4.1 Mononuclear Phagocyte Inflammation and Neurotoxicity |
|
|
257 | (18) |
|
|
|
|
|
4.2 Neurotoxicity of HIV-1 Proteins |
|
|
275 | (14) |
|
|
|
|
|
|
4.3 HIV-1 and Tat: Neuropathogenesis and Therapeutic Targets |
|
|
289 | (16) |
|
|
|
|
|
|
305 | (13) |
|
|
|
|
|
|
4.5 HIV-1 and Cannabinoids |
|
|
318 | (11) |
|
|
|
|
329 | (9) |
|
|
|
338 | (16) |
|
|
|
|
|
|
|
|
|
|
354 | (11) |
|
|
|
|
|
|
5.1 Simian Immunodeficiency Virus |
|
|
365 | (12) |
|
|
|
|
|
|
5.2 Feline Immunodeficiency Virus |
|
|
377 | (14) |
|
|
5.3 Caprine Arthritis Encephalitis Virus and Visna |
|
|
391 | (10) |
|
|
Sigurbjorg Torsteinsdottir |
|
|
|
|
401 | (13) |
|
|
|
5.5 Murine Models for NeuroAIDS |
|
|
414 | (17) |
|
|
5.6 Simian Immunodeficiency Virus and Opiates |
|
|
431 | (7) |
|
|
|
|
|
5.7 SIV and FIV Models of Peripheral Neuropathy |
|
|
438 | (8) |
|
|
|
|
|
5.8 Animal Models and Bioimaging |
|
|
446 | (17) |
|
|
|
|
Section 6 Personal Perspectives In Living with HIV/AIDS |
|
|
|
6.1 HIV and My Mental Health---A Personal Reflection |
|
|
463 | (3) |
|
|
6.2 Fear and Loathing in HIV Mental Health Care |
|
|
466 | (3) |
|
|
|
469 | (3) |
|
|
6.4 HIV Dementia: A Patient's Perspective. Living with the Suffering, the Diagnosis, and the Uncertainties |
|
|
472 | (3) |
|
|
6.5 My Virus Just Turned Twenty-One: A Woman's Perspective of the Long-term Psychological Impact of Living with HIV |
|
|
475 | (6) |
|
|
Section 7 Clinical and Pathologic Manifestations of Disease |
|
|
|
7.1 Perspective on HIV CNS Infections |
|
|
481 | (7) |
|
|
7.2 HIV-Associated Neurocognitive Disorders |
|
|
488 | (16) |
|
|
|
7.3 The CNS in Acute and Early Infection |
|
|
504 | (14) |
|
|
|
518 | (18) |
|
|
|
7.5 Peripheral Neuropathy |
|
|
536 | (10) |
|
|
|
|
|
546 | (5) |
|
|
|
|
551 | (16) |
|
|
|
|
|
|
567 | (14) |
|
Virawudh Soontornniyomkij |
|
|
|
|
581 | (20) |
|
|
Section 8 Pathogenesis of Comorbid Conditions |
|
|
|
8.1 NeuroAIDS as an Inflammatory Disorder |
|
|
601 | (18) |
|
|
|
|
|
8.2 Neuronal Injury, White Matter Disease, and Neurotrophic Factors |
|
|
619 | (14) |
|
|
|
|
8.3 Pathobiology of HIV-related Neuropathies |
|
|
633 | (10) |
|
|
|
|
643 | (18) |
|
|
|
8.5 Opportunistic Infections |
|
|
661 | (60) |
|
|
|
8.6 Progressive Multifocal Leukoencephalopathy |
|
|
721 | (8) |
|
|
|
|
729 | (16) |
|
|
|
|
745 | (7) |
|
|
|
8.9 HIV and Psychiatric Comorbidities |
|
|
752 | (11) |
|
|
|
Section 9 Diagnostics and Biomarkers |
|
|
|
|
763 | (35) |
|
|
|
|
9.2 Magnetic Resonance Imaging |
|
|
798 | (12) |
|
|
|
Christine Fennema-Notestine |
|
|
9.3 Psychological Evaluations |
|
|
810 | (15) |
|
|
|
|
9.4 Viral and Cellular Biomarkers during Antiretroviral Therapy |
|
|
825 | (22) |
|
|
|
|
847 | (9) |
|
|
|
9.6 Viral Clades: Role in HIV Neuropathogenesis |
|
|
856 | (5) |
|
|
|
9.7 Proteomics and Biomarkers |
|
|
861 | (14) |
|
|
|
|
Section 10 Children and Adolescents |
|
|
|
10.1 Clinical and Pathological Features of HIV-1 Encephalopathy in Children and Adolescents |
|
|
875 | (32) |
|
|
|
|
10.2 Infants, Children, and Adolescents: Nervous System Disease in the Era of Combination Antiretroviral Therapy |
|
|
907 | (18) |
|
|
|
10.3 Psychosocial Aspects of Neurological Impairment in Children with AIDS |
|
|
925 | (12) |
|
|
|
10.4 Growing Up with HIV Disease |
|
|
937 | (8) |
|
|
|
|
Section 11 Antiretroviral and Adjunctive Therapies |
|
|
|
11.1 Current Concepts in the Treatment of HIV Infection with Focus on Brain Disease |
|
|
945 | (17) |
|
|
|
11.2 Pharmacology of Antiretroviral Therapies |
|
|
962 | (16) |
|
|
|
|
|
|
11.3 Treatment of Opportunistic Infections Associated with Human Immunodeficiency Virus Infection |
|
|
978 | (9) |
|
|
11.4 Nanoformulated Medicines |
|
|
987 | (12) |
|
|
|
|
|
11.5 Antiretroviral Nanotherapies |
|
|
999 | (6) |
|
|
|
11.6 Adjunctive Medicines |
|
|
1005 | (12) |
|
|
|
Section 12 Psychiatry and Psychobiology |
|
|
|
12.1 Psychiatric Disorders |
|
|
1017 | (17) |
|
|
|
|
12.2 Neurocognition in HIV and Substance Use Disorders |
|
|
1034 | (11) |
|
|
|
|
12.3 Psychobiology of Risk Behavior |
|
|
1045 | (7) |
|
|
12.4 Everyday Impact of HIV-Associated Neurocognitive Disorders |
|
|
1052 | (14) |
|
|
|
|
|
12.5 Facing Legal and Ethical Challenges in the Treatment of AIDS |
|
|
1066 | (11) |
|
|
|
12.6 Neuropsychological Testing |
|
|
1077 | (10) |
|
|
|
|
|
12.7 The Impact of HIV Subtype and Cultural and Sociodemographic Factors on HIV-1 Infection and Associated Neuropathogenesis in Africa |
|
|
1087 | (12) |
|
|
|
Index |
|
1099 | |